Detalhe da pesquisa
1.
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
Haematologica
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572567
2.
Chimeric Antigen Receptor T-Cell Therapy and Imaging Applications for Large B-Cell Lymphoma.
Radiology
; 307(5): e221362, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37310248
3.
The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma.
J Hum Nutr Diet
; 36(5): 2099-2107, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37489541
4.
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Br J Haematol
; 198(3): 492-502, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35485402
5.
Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline.
Br J Haematol
; 204(1): 108-126, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880821
6.
Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease.
Br J Haematol
; 199(1): 40-44, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35894253
7.
Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience.
Br J Haematol
; 190(5): e279-e282, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32526039
8.
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Transplant Cell Ther
; 30(1): 77.e1-77.e15, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890589
9.
High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
Hemasphere
; 8(1): e29, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38434533
10.
Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma.
Mediterr J Hematol Infect Dis
; 15(1): e2023041, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37435036
11.
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
Blood Adv
; 7(12): 2872-2883, 2023 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724512
12.
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party.
Front Immunol
; 14: 1252811, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37828980
13.
Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity.
BMJ Neurol Open
; 2(1): e000054, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33681787
14.
An update on ICU outcomes in patients after CAR T therapy: A four-year tertiary UK centre experience.
J Crit Care
; 80: 154511, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38157684
15.
Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics.
Leuk Lymphoma
; 64(12): 2037-2041, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37602678
16.
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma.
Blood Adv
; 6(1): 321-326, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34700342
17.
Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Leuk Lymphoma
; 63(8): 1980-1984, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35481791
18.
Colitis After CAR T-Cell Therapy for Refractory Large B-Cell Lymphoma Responds to Anti-Integrin Therapy.
Inflamm Bowel Dis
; 27(4): e45-e46, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33252123
19.
Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma.
Hemasphere
; 5(3): e535, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33623881
20.
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group.
Leukemia
; 35(12): 3585-3588, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750508